Sandip Pravin Patel MD Professor (He/Him)

Oncology•La Jolla, CA

Hematologic Oncology, Thoracic Cancer, Clinical Informatics

Leader, Experimental Therapeutics Deputy Director, San Diego Center for Precision Immunotherap

Join to View Full Profile

3855 Health Sciences DriveLa Jolla, CA 92093
Phone+1 858-822-6580
Fax+1 858-822-6186

Summary

Early phase clinical trials of cancer immunotherapy, solid tumor cellular therapy, thoracic immunooncology, spatial immune profiling, irAEs

Education & Training

Duke University HospitalFellowship, Hematology and Medical Oncology, 2011 - 2014
UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Internal Medicine, 2008 - 2011
Baylor College of MedicineClass of 2008
Duke UniversityBA, Political Science, Magna Cum Laude, 2000 - 2004

Certifications & Licensure

CA State Medical License 2009 - 2027
NC State Medical License 2011 - 2014
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Commendation for Excellence in Medical Student Teaching 2008 - 2009, 2009
“Most Awards” Award 2008 - 2009, 2009
Dean’s List 2000 - 2001, 2000 - 2002, 2002
Dean’s List w/t Distinction 2002
Killson Educational Foundation Scholarship
Phi Beta Kappa National Academic Honor Society
Pi Sigma Alpha National Political Science Honor Society
Goldwater Scholarship semifinalist for Duke University
National Merit Scholarship Winner, National Advanced Placement Scholar with Distinction High School
National Qualifier for Quiz Bowl, Fourth place at national TEAMS engineering contest, State Qualifier for Debate
Join now to see all

Clinical Trials

Phase 1/2 Study of X-396, an Oral ALK Inhibitor, in Patients With ALK-positive Non-Small Cell Lung Cancer Start of enrollment: 2012 Jun 01
Completed
Phase 1, Phase 2
A Study of Galunisertib (LY2157299) in Combination With Nivolumab in Advanced Refractory Solid Tumors and in Recurrent or Refractory NSCLC, or Hepatocellular Carcinoma Start of enrollment: 2015 Jan 01
Completed
Phase 1, Phase 2
An Investigational Immuno-therapy Study of BMS-986205 Given in Combination With Nivolumab and in Combination With Both Nivolumab and Ipilimumab in Cancers That Are Advanced or Have Spread Start of enrollment: 2016 Apr 14
Completed
Phase 1, Phase 2
An Investigational Immuno-therapy Study to Test Combination Treatments in Patients With Advanced Non-Small Cell Lung Cancer Start of enrollment: 2016 May 09
Terminated
Phase 2
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Start of enrollment: 2017 Jan 30
ACTIVE_NOT_RECRUITING
PHASE2
An Investigational Immunotherapy Study of BMS-986299 Alone and in Combination With Nivolumab and Ipilimumab in Participants With Solid Cancers That Have Spread or Cannot be Removed Start of enrollment: 2018 Apr 05
Terminated
Phase 1
Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine Start of enrollment: 2018 Aug 29
Completed
Phase 1, Phase 2
A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC Start of enrollment: 2018 Dec 27
ACTIVE_NOT_RECRUITING
PHASE1
A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors Start of enrollment: 2022 Apr 14
TERMINATED
PHASE1, PHASE2
Roles: Principal Investigator
A Study of Dazostinag as Single Agent and Dazostinag in Combination With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors Start of enrollment: 2020 Jul 22
ACTIVE_NOT_RECRUITING
PHASE1, PHASE2
Roles: Principal Investigator
Join now to see all

Publications & Presentations

PubMed

1 citations
First cycle toxicity and survival in patients with rare cancers treated with checkpoint inhibitors.
Megan Othus, Sandip P Patel, Young Kwang Chae, Eliana Dietrich, Howard Streicher
Journal of the National Cancer Institute. 2025-04-01
1 citations
Intratumoral or Subcutaneous MK-2118, a Noncyclic Dinucleotide STING Agonist, with or without Pembrolizumab, for Advanced or Metastatic Solid Tumors or Lymphomas.
Jason J Luke, Randy F Sweis, J Randolph Hecht, Reva Schneider, Mark N Stein
Clinical Cancer Research. 2025-04-01
Proceedings of the 1st biannual bridging the gaps in lung cancer conference.
Narjust Florez, Sandip P Patel, Heather Wakelee, Lyudmila Bazhenova, Erminia Massarelli
The Oncologist. 2025-02-06

Abstracts/Posters

Photocrosslinkable Polymers for Biomedical Applications.
Grinstaff MW, Carnahan PS, Fleming DL, Hatchell NR, Luman MT, Patel SP, 222nd American Chemical Society
Abstract #896 appears in Blood, Volume 106, issue 11.
Travel grant recipient and poster presentation, American Society of Hematology Conference 2005
Empiric treatment as a means of diagnosis in AIDS patients with CNS lesions.
Poster Presentation, Society of General Internal Medicine Conference 2009

Lectures

SWOG 1609 (DART): A phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors.
2019 ASCO Annual Meeting - 6/1/2019

Press Mentions

What 3 Big Highlights from the 2025 European Lung Cancer Conference Mean for PracticeApril 7th, 2025
FDA Approval, Big News Complicate EGFR-Mutated NSCLC DecisionsFebruary 24th, 2025
2025’s Most Anticipated Advances in Lung Cancer Care: What’s NextJanuary 3rd, 2025
Join now to see all